Healthcare >> Analyst Interviews >> April 9, 2001

Specialty Pharmaceuticals: Ken Laudan – Robinson Humphrey Company Llc

KEN LAUDAN joined Robinson-Humphrey in 2000. He has 10 years of healthcare investment experience including Senior Research Analyst positions at Montgomery Securities (now Banc of America Securities) and Hambrecht & Quist (now Chase H&Q). Since 1992, Mr. Laudan has been involved with nearly $2 billion worth of healthcare equity and M&A assignments consisting of 15 different healthcare companies. He also is a three-time Wall Street Journal All-Star Analyst. Mr. Laudan received a BS Finance/Accounting from Kansas State University in 1982. Profile
TWST: What distingushes your approach to the specialty pharma and pharma

services grouping?

Mr. Laudan: It's really a hybrid portfolio of companies, but with all of

them prescription drug- or